Company Overview and News

 
Rift Valley Resources’ drilling targets large NdPr resource at Angolan project

2018-08-28 proactiveinvestors.com.au
Rift Valley Resources Ltd (ASX:RVY) has begun a reverse circulation (RC) drilling program targeting a large tonnage, high-grade NdPr resource at the Longonjo project in Angola.
LYC LYSCF LYSDY RVY

 
Diggers and Dealers Mining Forum focuses on growth, exploration and acquisitions

2018-08-10 proactiveinvestors.com.au
Diggers and Dealers Mining Forum 2018 is done and dusted, but what were some highlights? We take a look.
PLS LYC PILBF TGN LYSCF EOHDF EVN AGODY AMSLF FSUGY RSG AUZ AGO EHL FSUMF RMGGY LYSDY ATLGF RMGGF CAHPF FMG

 
Rift Valley Resources' upcoming drilling program aimed at growing magnet metals resource

2018-07-17 proactiveinvestors.com.au
Rift Valley Resources Ltd (ASX:RVY) is about to undertake 9,000 metres of drilling at the Longonjo Magnet Metals Project in Angola and has outlined the work to its local administration.
LYC RVY

 
Rift Valley Resources outlines 9,000-metre drill program to grow magnet metals deposit

2018-06-05 proactiveinvestors.com.au
Rift Valley Resources Ltd (ASX:RVY) has designed a 9,000-metre drill program to evaluate its Longonjo Magnet Metals Project in Angola.
LYC RVY

 
Rift Valley Resources appoints new chair to head-up magnet metals strategy

2018-05-14 proactiveinvestors.com.au
Rift Valley Resources Ltd (ASX:RVY) has appointed accomplished resources executive Paul Atherley as non-executive chairman as it increases its focus on the Longonjo Magnet Metal Project in Angola.
LYC LRL LYRSY BKY RVY BKY LYSYF

 
Nasdaq Hosted 2nd Nasdaq International Designation Virtual Investor Conference

2018-04-03 globenewswire
NEW YORK, April 03, 2018 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (Nasdaq:NDAQ) announced the conclusion of its Nasdaq International Designation Virtual Investor Conference on March 21, 2018. In collaboration with BNY Mellon Depositary Receipts, Nasdaq welcomed select BNY Mellon Level I ADR Issuers from Australia and New Zealand to present their current state of business to a broad audience, including potential investors.
SPHRY LYC SPHRF LYSCF LYSDY SPL SBM STBMY

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to ASX:LYC / LYNAS CORPORATION LIMITED on message board site Silicon Investor.

Polycom Inc. Polycom Inc. Polycom Inc. Molycorp - The Owner of the biggest US rare earth deposit Molycorp - The Owner of the biggest US rare earth deposit Molycorp - The Owner of the biggest US rare earth deposit
PLYCF Playstar Corporation (Premier Mobile Technologies) SMS PLYCF Playstar Corporation (Premier Mobile Technologies) SMS PLYCF Playstar Corporation (Premier Mobile Technologies) SMS GlycoGenesys GLGS (formerly SafeScience SAFS) GlycoGenesys GLGS (formerly SafeScience SAFS) GlycoGenesys GLGS (formerly SafeScience SAFS)
GlycoBiology GlycoBiology GlycoBiology Oxford GlycoSciences Plc Oxford GlycoSciences Plc Oxford GlycoSciences Plc
Lycos Lycos Lycos Flycast Communications Corporation (FCST) Flycast Communications Corporation (FCST) Flycast Communications Corporation (FCST)
clyc--Projected 97 sales $600mil, 96 sales $5mil clyc--Projected 97 sales $600mil, 96 sales $5mil clyc--Projected 97 sales $600mil, 96 sales $5mil USA/Lycos USA/Lycos USA/Lycos